ReviewCells2019
Microbiome, Parkinson's Disease and Molecular Mimicry.
Review in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- What Are the Key Gut Microbiota Involved in Neurological Diseases? A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Pooled it
- The role of gut microbiome in aging-associated diseases: where do we stand now and how technology will transform the future.Gut microbes · 2026Review
- The Parkinson's pandemic: prioritizing environmental policy and biological resilience via the gut.The Journal of clinical investigation · 2026Article
- The Progress of Active Immunotherapy for Parkinson's Disease.International journal of molecular sciences · 2026Review
- Parkinson's Disease and the Microbiota-Gut-Brain Axis: Metabolites, Mechanisms, and Innovative Therapeutic Strategies Targeting the Gut Microbiota.Molecular neurobiology · 2025Review
- The application of fecal microbiota transplantation in Parkinson's disease.Frontiers in aging neuroscience · 2025Review
- Gut Microbiota and Immune System Dynamics in Parkinson's and Alzheimer's Diseases.International journal of molecular sciences · 2024Review
- Physiopathological Roles of White Adiposity and Gut Functions in Neuroinflammation.International journal of molecular sciences · 2024Review
- Mapping the global research landscape on molecular mimicry: a visualization and bibliometric study.Journal of translational medicine · 2024Article
- Review
- Ozone Environmental Pollution: Relationship between the Intestine and Neurodegenerative Diseases.Antioxidants (Basel, Switzerland) · 2023Review
- New Pieces for an Old Puzzle: Approaching Parkinson's Disease from Translatable Animal Models, Gut Microbiota Modulation, and Lipidomics.Nutrients · 2023Review
- Mutant and curli-producing E. coli enhance the disease phenotype in a hSOD1-G93A mouse model of ALS.Scientific reports · 2023Article
- Evaluation of the Oral Bacterial Genome and Metabolites in Patients with Wolfram Syndrome.International journal of molecular sciences · 2023Article
- Gut-brain axis: gut dysbiosis and psychiatric disorders in Alzheimer's and Parkinson's disease.Frontiers in neuroscience · 2023Review
- Association of Diet and Physical Activity With All-Cause Mortality Among Adults With Parkinson Disease.JAMA network open · 2022Article
- Computational approach to modeling microbiome landscapes associated with chronic human disease progression.PLoS computational biology · 2022Article
- Gut-Brain Axis as a Pathological and Therapeutic Target for Neurodegenerative Disorders.International journal of molecular sciences · 2022Review
- A Comprehensive Review on the Role of the Gut Microbiome in Human Neurological Disorders.Clinical microbiology reviews · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's Disease (PD) is typically classified as a neurodegenerative disease affecting the motor system. Recent evidence, however, has uncovered the presence of Lewy bodies in locations outside the CNS, in direct contact with the external environment, including the olfactory bulbs and the enteric nervous system. This, combined with the ability of alpha-synuclein (αS) to propagate in a prion-like manner, has supported the hypothesis that the resident microbial community, commonly referred to as microbiota, might play a causative role in the development of PD. In this article, we will be reviewing current knowledge on the importance of the microbiota in PD pathology, concentrating our investigation on mechanisms of microbiota-host interactions that might become harmful and favor the onset of PD. Such processes, which include the secretion of bacterial amyloid proteins or other metabolites, may influence the aggregation propensity of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.